TheraRadar
← Back
Data updated: Jul 17, 2026

ASCOT

Generics

ASCOT is a generic drug manufacturer focused on Cardiovascular, Gastroenterology, Neurology.

1983
Since
18
Drugs
-
Trials
0
New Drugs (2yr)

ASCOT's Key Drugs

ASCOT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ASCOT's Recent FDA Approvals

New NDA/BLA approvals for ASCOT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ASCOT's Therapeutic Areas

ASCOT's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 40%
2 drugs
Gastroenterology 20%
1 drugs
Neurology 20%
1 drugs
Ophthalmology 20%
1 drugs

ASCOT's Top Competitors

ASCOT's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Novartis, and VALIDUS PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ASCOT Pipeline Snapshot

Active clinical trials for ASCOT across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling